Table 1.

Demographic, virologic and immunologic characteristics of HCV-infected patients.

Patient			HCV-infection		HCV-RNA		HCV-specific IgG
	ID	age, gender	route a	durationb	serum	B-cells	anti-E1E2H77 c	neutralization to HCVpp-H77 (IC50)d
					(IU/ml)	(IU/106 B-cells)
gt1a	P01	30, M	IDU	1y	6,74 106	<46	< 10	< 50%
	P02	28, F	IDU	≤ 1y	1,42 106	<46	< 10	< 50%
	P32	36, F	IDU	5m	1,29 107	3,51 104	559	< 50%
	P03	34, M	IDU	1y 4m	5,30 106	9,54 104	4898	4065
	P05e	47, F	IDU	25y	3,70 106	2,15 104	90991	3311
	P15_2009f	28, M	IDU	3y	5,00 106	1,11 105	30440	21616
gt1b	P06	64, M	transfusion	>10y	1,25 107	5,60 104	259	< 50%
	P08e	68, F	transfusion	30y	2,18 106	8,28 104	30339	14286
	P09	64, M	transfusion	15y	8,91 105	1,91 104	3040	1858
	P10	47, M	transfusion	28y	1,40 106	6,52 103	35727	6250
	P11	66, M	transfusion	20y	2,02 106	6,46 103	4046	922
	P12e	28, F	IDU	≥ 5y	3,74 105	4,31 103	16218	6361
gt3a	P13	26, M	IDU	1y	5,41 105	<46	< 10	< 50%
	P14	33, M	IDU	3m	2,88 106	2,42 104	109	< 50%
	P15_2006f	25, M	IDU	4m	2,29 107	1,46 105	165	< 50%
	P16	31, M	IDU	≥ 5y	9,76 105	3,38 104	3396	513

^aIDU, injecting drug use. ^bTime elapsed between initial HCV-infection/diagnosis and biological sampling for the present study (y, year; m, month). ^cAnti-E1E2_H77 IgG levels are expressed as reciprocal endpoint dilution titer of autologous serum in EIA; <10, IgG was not detected at serum-dilution 1/10. ^dNeutralizing activities of autologous serum to HCV-pseudoviral particles expressing envelope proteins of gt1a (HCVpp_H77) are expressed as IC₅₀ (reciprocal titer); <50%, neutralization did not reach 50%. ^eSerum and B cells from patients P05, P08 and P12 were sampled at multiple time points, only 1 time-point is shown. ^fPatient P15, initially infected with gt3a, experienced a HCV-super-infection with gt1a and has donated biological specimens twice with a 3-year interval.